Astria Therapeutics Files Definitive Proxy Statement
| Field | Detail |
|---|---|
| Company | Astria Therapeutics, Inc. |
| Form Type | DEF 14A |
| Filed Date | Apr 28, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: proxy-statement, governance, annual-meeting
Related Tickers: ATRS
TL;DR
Astria Therapeutics (ATRS) filed its proxy statement for the June 11 meeting. Vote your shares!
AI Summary
Astria Therapeutics, Inc. filed its definitive proxy statement on April 28, 2025, for its annual meeting of stockholders scheduled for June 11, 2025. The filing, under the SEC Act of 1934, concerns the election of directors and other corporate matters. The company, formerly Catabasis Pharmaceuticals Inc., is headquartered at 22 Boston Wharf Road, Boston, MA.
Why It Matters
This filing provides shareholders with crucial information regarding the company's governance and upcoming voting matters, impacting their ability to make informed decisions about the company's future.
Risk Assessment
Risk Level: low — This is a routine proxy filing and does not contain new material financial or operational information.
Key Players & Entities
- Astria Therapeutics, Inc. (company) — Registrant
- Catabasis Pharmaceuticals Inc (company) — Former company name
- 20250611 (date) — Annual meeting date
- 20250428 (date) — Filing date
FAQ
What is the purpose of this DEF 14A filing?
This filing is a definitive proxy statement filed by Astria Therapeutics, Inc. for its annual meeting of stockholders.
When is the annual meeting of stockholders scheduled to take place?
The annual meeting of stockholders is scheduled for June 11, 2025.
What is the filing date of this proxy statement?
The definitive proxy statement was filed on April 28, 2025.
What is the company's former name?
The company was formerly known as Catabasis Pharmaceuticals Inc.
Where is Astria Therapeutics, Inc. located?
The company's business and mail address is 22 Boston Wharf Road, 10th Floor, Boston, MA 02210.
Filing Details
This Form DEF 14A (Form DEF 14A) was filed with the SEC on April 28, 2025 regarding Astria Therapeutics, Inc..